• ARCA Biopharma Inc., of Broomfield, Co., filed for a public offering of $20 million in stock and warrants to fund the Phase IIb portion of the GENETIC-AF trial of Gencaro (bucindolol hydrochloride) for atrial fibrillation. Dawson James Securities Inc. is the lead placement agent.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter